Theravance Biopharma
new study in patients with cypress | Theravance Biopharma
Company
Deck Type
Sector
Industry
Deck date
November 2022
Slide
44 of 44
Related slides by other companies
Nuvalent
Investor Presentation
April 2024
lated cone program status pivotal data naive and first approved product study for phase ongoing with registrational intent for patients with execute on global registrational strategies additional discovery research programs ongoing mission bringing new best in class medicines to patients with cancer treated alk planned development in naive setting phase ongoing with registrational intent for patients with study for alk planned phase initiation in i he | Nuvalent
Equillium
Investor Presentation
August 2023
phase first in human study of single ascending dose multiple ascending dose proof of concept study in celiac disease patients | Equillium
Nuvalent
Investor Presentation
January 2024
coal execute on global first pivotal registrational data strategies first approved product mission bringing new potential best in class medicines to patients with cancer anticipated milestones progress phase with registrational intent initiate phase with registrational intent initiate phase trial for launch alk strategy and alk programs interim data for both her program i | Nuvalent
NeuroSense Therapeutics
Investor Presentation
January 2024
randomized prospective double blind placebo controlled study phase design placebo controlled road | NeuroSense Therapeutics
Other recent decks by Theravance Biopharma
See all presentations (5 decks)
Results
August 2023
Results
May 2023
Investor Conference
April 2023
Results
February 2023
Search Thousands of Presentations by World Leading Companies
Trending:
Addressable Market
Ecosystem
Beauty Market
WACC
NFT
Management Team
Investment Highlights